Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

First anticancer monoclonal antibody approved by FDA

Nov. 27, 1997

Results from Leuvectin trial in kidney cancer patients reported

Nov. 26, 1997

Phase I trial of multiple-dose IDEC-C2B8 in NHL

Nov. 24, 1997

International phase III trial of Maxamine in malignant melanoma

Nov. 18, 1997

Evidence that Theratope elicits an antitumor cellular immune response presented

Nov. 18, 1997

FDA approves Intron A for non-Hodgkin's lymphoma

Nov. 12, 1997

AntiVirals to acquire ImmunoTherapy and its late-stage cancer vaccine

Nov. 7, 1997

Phase I trials begin on TNT in glioma patients

Nov. 6, 1997

Novopharm Biotech cleared for phase I trials of melanoma immunotherapy

Oct. 30, 1997

Antitumor activity of LC-9018 correlated with cytokine production

Oct. 28, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...